Microvascular Dysfunction Assessment to Predict Left Ventricular Reverse Remodeling (MICROREV)

Integrated University Hospital Trust of Verona

Status

Enrolling

Conditions

Heart Failure

Left Ventricular Dysfunction

Idiopathic Dilated Cardiomyopathy

Treatments

Diagnostic Test: Thermodilution based assessment of coronary microcirculation

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT06356727

121CET-MICROREV-DCM

Details and patient eligibility

About

Patients presenting with idiopathic dilated cardiomyopathy and left ventricle dysfunction (LVEF <40%), naive of anti-remodeling cardiac medical therapy, will undergo invasive coronary microvascular assessment based on thermodilution. The primary endpoint, namely the left ventricle reverse remodeling, will be assessed after 12 months of optimal medical therapy based on transthoracic echocardiography. The primary endpoint will be evaluated by an independent central core lab. Patients enrolled in the study will be followed for a period of 5 years to monitor their clinical status. During the study period participants may undergo multimodality diagnostic tests including ECG telemetry monitoring, cardiopulmonary exercise testing, cardiovascular cardiac magnetic resonance.

Full description

This is a prospective, multicentric, single-arm explorative clinical study in patients presenting with heart failure and idiopathic dilated cardiomyopathy with LVEF ≤ 40%. Patients identified as eligible for the protocol will be asked for written informed consent to participate in the study.

After appropriate treatment of the acute heart failure phase, participants will undergo coronary angiography to rule out obstructive coronary disease.

Fractional flow reserve (FFR) will be assessed as per standard clinical practice and a value ≤ 0.80 will be considered abnormal. Microvascular assessment will be performed using the same pressure/thermodilution guidewire used for FFR assessment with the derivation of coronary flow reserve (CFR), index of microcirculatory resistance (IMR) and the microvascular resistance reserve (MRR).

Steady-state hyperemia will be obtained using an intravenous adenosine infusion or intracoronary papaverine as per routine clinical practice.

The primary endpoint will be assessed based on the variation of echocardiographic indices from the baseline to 12-month follow up. Transthoracic echocardiography will be performed to confirm the diagnosis and obtain information about adverse cardiac remodeling and after 12 months of optimal medical therapy to evaluate reverse remodeling.

Patients will be clinically managed by a dedicated heart failure team to optimize medical therapy and organize the follow-up.

Patients enrolled in the study will be clinically followed for a period of 5 years to monitor the clinical status and report major adverse cardiac events.

During the study period participants may undergo multimodality diagnostic tests according to the recent international guidelines. Data from these tests will be collected if the test will be performed per clinical practice:

3-leads ECG telemetry monitoring (or 24 hours Holter ECG) to detect or quantify atrial and/or ventricular arrhythmias during the hospitalization. N-terminal pro-B-type natriuretic peptide (NT - proBNP). Cardiopulmonary exercise testing (CPET) to assess functional capacity. Contrast enhanced cardiac magnetic resonance. CMR assessment may be repeated at 12 months follow-up. Genetic counseling and genetic testing, performed by an appropriately trained healthcare professional is recommended in patients with idiopathic DCM by the latest international guidelines to enable diagnosis, prognostication, therapeutic stratification.

Enrollment

190 estimated patients

Sex

All

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female, aged >18 years
First diagnosis of idiopathic DCM (defined according to the most recent ESC Guidelines) with LVEF ≤ 40% and clinical indication to diagnostic coronary angiography
Willing and able to give informed consent for participation in the study

Exclusion criteria

Obstructive CAD (defined as angiographically intermediate disease [50%-70%] with impaired FFR or as angiographically severe disease [>70%] in 1 or more epicardial vessels)
History of previous myocardial infarction, percutaneous revascularization or coronary-aortic bypass graft (CABG) surgery
Valvular heart disease (rheumatic heart disease, severe aortic stenosis, severe aortic regurgitation, severe primary mitral regurgitation)
Infective endocarditis
Congenital heart disease
Peripartum cardiomyopathy
Acute myocarditis (detected by endomyocardial biopsy - histological criteria - or by CMR - Lake Louis criteria) and pericarditis
Persistent tachyarrhythmias (documented persistent high-rate supraventricular arrhythmias)
Excessive alcohol intake (>80 g/die for at least five years)
History of chemotherapy (anthracycline therapy, cumulative dosages >250 mg/m2)
History of uncontrolled arterial hypertension (blood pressure >160/100 mmHg)
Stage IV and V of chronic kidney disease (eGFR < 30 ml/min, estimated through CKD - EPI Creatinine Equation)
Allergy or other contraindication to iodinated contrast and/or adenosine
Chronic resting O2 saturation <85%
Pregnancy or suspected pregnancy